Mounjaro Gains Ground in Competitive Weight-Loss Arena

PharmaTrac, a market research firm, published data on Eli Lilly’s weight-loss drug Mounjaro has seen rapid growth in India just a month after its launch, with sales of the 2.5 mg injection jumping from Rs. 1.42 crore in March to Rs. 4.8 crore in April.

This rapid acceptance emphasizes the strong demand for weight-loss treatments in a country facing a growing obesity crisis; over 80 million Indians are observed to have the issue for the same. Yet, doctors remain cautious. Medical experts say while drugs like Mounjaro and Wegovy. Momentarily, in Indian markets, Novo Nordisk’s obesity medication is expected to release. These have been game-changers globally, and their long-term effectiveness and side effects on Indian patients remain to be seen.

Dr. Neeraj Tulra, an internal medicine and infectious disease specialist at LH Hiranandani Hospital, Mumbai, said that these medications have created a major buzz in Western countries, and naturally, people in India have been eager to try them, but it usually takes about four- six months to evaluate the sustained weight loss, weight regain after discontinued and how well patients tolerate them.

He noted that India’s population has a distinct physiological and dietary profile, which could influence how patients respond to these treatments compared to Western users.

Dr. Anurag Lila, a visiting endocrinologist at the same hospital, highlighted the scale of the problem and that Mounjaro is a promising drug which has already been used widely abroad with clinical trials backing it. Its arrival in India has been highly anticipated for obesity, which is practically a pandemic in India, and diabetes is highly dominant.

Still, doctors agree that while the initial numbers are hopeful, a longer observation period is necessary to define the true impact of these medications in the Indian context.